~~<i id='1FD8CD71FD'><strike id='1FD8CD71FD'><tt id='1FD8CD71FD'><pre id='1FD8CD71FD'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

comprehensive

author：leisure time 2025-09-30 00:36:47 - browse：4653

AP/Richard Drew

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.

The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.

Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： California Joshua trees severely burned in massive wildfire

knowledge

focus

hotspot

leisure time

hotspot

4:33NinemembersofCongressandotherswaittoenterMarjoryStonemanDouglasHighSchool,Friday,Aug.4,2023,inPa

WSS

Scientists find bacteria from stomach of ancient iceman

Jesse Tyler Ferguson makes friendship bracelets for Taylor Swift's Eras Tour

California Joshua trees severely burned in massive wildfire

Teen charged with murder as hate crime in killing of NYC dancer O'Shae Sibley: Sources

'Cuddling' is just what the doctor ordered for a 200

California Joshua trees severely burned in massive wildfire

leisure time

comprehensive

knowledge

Apple is now the first public company to be valued at $3 trillion

Climate activists disrupt London Pride march to protest corporate sponsorship

Medical leaders decry Supreme Court decision on affirmative action

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Eat, drink, but be wary — 4 foods that interact with medications

Medical records are filled with copy

New company forms to vet health AI models, root out weaknesses

The cancer drug shortage isn’t new — and neither are the solutions

Pope greeted like rockstar, appears revitalized at 'Catholic Woodstock' in Portugal

focus

Pfizer plans to depart BIO

What causes an itch? Researchers may have solved the mystery

Scientists find bacteria from stomach of ancient iceman

AI models in health care face new federal disclosure requirements

What causes an itch? Researchers may have solved the mystery

In diabetes hearing, Sanders takes on a new foe: food makers

hotspot

leisure time

hotspot

hotspot